Physician profile
Michael Shane Scott
NPI 1275535551
$1,251.35
in general payments reported to CMS, 2019-2025
25 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.10 · 2020: $147 · 2021: $164 · 2022: $224 · 2023: $209 · 2024: $223 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $629.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $184.12 | 2022-2025 | Ubrelvy, Qulipta |
| Amgen INC. | $138.87 | 2019-2025 | Otezla, Repatha, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $119.41 | 2020-2022 | |
| Pfizer INC. | $111.35 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $89.32 | 2022-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Supernus Pharmaceuticals, INC. | $77.57 | 2021-2024 | Qelbree |
| Inspire Medical Systems, INC. | $63.11 | 2024 | Inspire |
| Ge Healthcare | $62.86 | 2025 | |
| Glaxosmithkline, LLC. | $60.79 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sanofi Pasteur INC. | $48.62 | 2020-2023 | |
| Boston Scientific Corporation | $48.45 | 2024 | |
| Shire North American Group INC | $39.00 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $25.01 | 2023 | Dysport |
| Lilly USA, LLC | $23.51 | 2020 | |
| Tris Pharma INC | $19.45 | 2023 | Dyanavel Xr |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $18.44 | 2023 | Azstarys |
| Acadia Pharmaceuticals INC | $17.30 | 2020 | |
| Heartflow, INC. | $14.81 | 2024 | |
| Exact Sciences Corporation | $14.17 | 2025 | Cologuard Collection Kit |
| Vbi Vaccine (Delaware) INC. | $13.51 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $12.75 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.69 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.64 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $12.39 | 2021 | |
| Celgene Corporation | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.